Open‐label Phase I clinical trial of AAV2‐BDNF gene therapy is ongoing to assess the safety, tolerability, and preliminary efficacy of AAV2‐BDNF stereotaxic brain injection in early AD and Mild Cognitive Impairment (MCI). This evidence concerns the gene BDNF and Cognitive impairment.